MA28971B1 - Oligosaccharides d'algine et derives de ceux-ci ainsi que leur fabrication et leur utilisation - Google Patents

Oligosaccharides d'algine et derives de ceux-ci ainsi que leur fabrication et leur utilisation

Info

Publication number
MA28971B1
MA28971B1 MA29402A MA29402A MA28971B1 MA 28971 B1 MA28971 B1 MA 28971B1 MA 29402 A MA29402 A MA 29402A MA 29402 A MA29402 A MA 29402A MA 28971 B1 MA28971 B1 MA 28971B1
Authority
MA
Morocco
Prior art keywords
derivatives
oligosaccharide
alginate
manufacture
alginate oligosaccharide
Prior art date
Application number
MA29402A
Other languages
English (en)
Inventor
Meiyu Geng
Xianliang Xin
Guangqiang Sun
Original Assignee
Ocean Univ China
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocean Univ China filed Critical Ocean Univ China
Publication of MA28971B1 publication Critical patent/MA28971B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/033—Uronic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention divulgue un oligosaccharide d'alginate et ses dérivés avec un degré de polymérisation compris dans la marge de 2 à 22. L'oligosaccharide d'alginate est constitué de l'acide (beta)-D-mannuronique lié par des liaisons 1-4 glycosidiques. Les dérivés avec le terminal réduit à la position 1 du radical carboxyle peuvent être préparés par dégradation oxydante. La présente invention divulgue également un procédé de fabrication de l'oligosaccharide d'alginate et de ses dérivés, qui inclut les procédures qui consistent à faire réagir une solution d'alginate pendant 2 à 6 heures dans un autoclave à un pH 2-6 et à la température de 100 à 120°C, et à ajuster le pH à 7 après l'arrêt de la réaction, après quoi l'oligosaccharide résultant est oxydé en présence d'un oxydant pour obtenir un produit de dégradation oxydante. L'oligosaccharide d'alginate de l'invention et ses dérivés peuvent être utilisés dans la fabrication d'un médicament pour la prophylaxie et le traitement de la maladie d'Alzheimer MA et du diabète.
MA29402A 2004-03-24 2006-10-20 Oligosaccharides d'algine et derives de ceux-ci ainsi que leur fabrication et leur utilisation MA28971B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2004100238270A CN1562050A (zh) 2004-03-24 2004-03-24 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用

Publications (1)

Publication Number Publication Date
MA28971B1 true MA28971B1 (fr) 2007-11-01

Family

ID=34480338

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29402A MA28971B1 (fr) 2004-03-24 2006-10-20 Oligosaccharides d'algine et derives de ceux-ci ainsi que leur fabrication et leur utilisation

Country Status (19)

Country Link
US (4) US8835403B2 (fr)
EP (1) EP1736160B1 (fr)
JP (1) JP4709203B2 (fr)
KR (1) KR100844918B1 (fr)
CN (1) CN1562050A (fr)
AU (1) AU2005223923B2 (fr)
BR (1) BRPI0509217B8 (fr)
CA (1) CA2561873C (fr)
DK (1) DK1736160T3 (fr)
EA (1) EA011417B1 (fr)
ES (1) ES2552218T3 (fr)
HU (1) HUE028071T2 (fr)
MA (1) MA28971B1 (fr)
NO (1) NO341226B1 (fr)
PL (1) PL1736160T3 (fr)
PT (1) PT1736160E (fr)
UA (1) UA85226C2 (fr)
WO (1) WO2005089776A1 (fr)
ZA (1) ZA200608813B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1562050A (zh) 2004-03-24 2005-01-12 中国海洋大学 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用
JP4599602B2 (ja) * 2005-04-13 2010-12-15 独立行政法人産業技術総合研究所 糖鎖構造を予測する方法
CN101889027B (zh) * 2007-12-29 2013-05-01 于传兴 低分子量海藻酸及其盐、应用、制法及药物组合物、食品
WO2012138698A1 (fr) * 2011-04-08 2012-10-11 Ancora Pharmaceuticals Inc. Synthèse d'oligosaccharides d'acide bêta-mannuronique
KR101395181B1 (ko) * 2011-08-02 2014-06-10 부경대학교 산학협력단 알긴산 유래 단량체 또는 중합체를 이용한 알긴산 분석법 및 이를 이용한 바이오매스로부터 추출된 알긴산 분석법
CN102936291B (zh) * 2012-11-15 2014-12-31 深圳大学 一种硒化聚甘露糖醛酸制备方法及其应用
JP6185157B2 (ja) * 2013-05-30 2017-08-23 蘇州科景生物医薬科技有限公司 多機能組成物並びにその作製方法及び使用
CA3228950A1 (fr) 2014-07-09 2016-01-14 Dsm Nutritional Products, Llc Compositions d'oligosaccharides et leurs procedes de production
FR3024358B1 (fr) * 2014-08-01 2017-11-10 Soc De Courtage Et De Diffusion Codif Int Compositions cosmetiques et complements alimentaires neuro-protecteurs comprenant de l'oligoalginate ayant un degre de polymerisation de 10 pour lutter contre le vieillissement de la peau.
WO2016122884A1 (fr) * 2015-01-26 2016-08-04 Midori Usa, Inc. Compositions à base d'oligosaccharides destinées à être utilisées comme ingrédients alimentaires et procédés de production de celles-ci
BR112017015944B1 (pt) 2015-01-26 2022-03-22 Cadena Bio, Inc Composição de ração animal, pré-mistura de ração animal, uso e método para produzir uma composição de ração animal
WO2016159554A1 (fr) * 2015-03-27 2016-10-06 전남대학교 산학협력단 Extrémité non réductrice d'oligosaccharides d'acide mannuronique insaturé et composition la contenant en tant qu'ingrédient actif
AU2016253010B2 (en) 2015-04-23 2021-06-10 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
CN106349298B (zh) * 2015-07-17 2021-02-09 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在改善睡眠障碍中的应用
CN106344593B (zh) * 2015-07-17 2020-01-10 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在制备治疗血管性痴呆药物中的应用
CN106344592A (zh) * 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用
JP7448174B2 (ja) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
KR20180094876A (ko) 2015-11-09 2018-08-24 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
JP7065516B2 (ja) 2015-11-09 2022-05-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのｎ末端エピトープおよびそれに対する立体配座選択的抗体
WO2017083520A1 (fr) * 2015-11-13 2017-05-18 Cadena Bio, Inc. Compositions alimentaires et thérapeutiques pour animaux et méthodes d'utilisation
CN105395563A (zh) * 2015-12-11 2016-03-16 青岛海洋生物医药研究院股份有限公司 低聚古罗糖醛酸及其衍生物在制备预防和治疗高脂血症及其并发症的药物和保健品中的应用
KR101862459B1 (ko) * 2016-06-21 2018-06-01 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당(ＯｌｉｇｏＭ)을 유효성분으로 포함하는 운동 능력 개선용 조성물
JP2019533426A (ja) 2016-07-18 2019-11-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
EA039078B1 (ru) * 2016-08-15 2021-11-30 Грин Вэли (Шанхай) Фармасьютикалз Ко., Лтд. Способ получения олигоманнуроновых дикислот
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018121559A1 (fr) 2016-12-30 2018-07-05 上海绿谷制药有限公司 Composition d'acide dicarboxylique mannuronique
WO2019014768A1 (fr) 2017-07-18 2019-01-24 The University Of British Columbia Anticorps anti-bêta-amyloïde
KR101893311B1 (ko) * 2017-11-23 2018-08-29 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당(ＯｌｉｇｏＭ)을 포함하는 당뇨의 예방 또는 치료용 조성물
CN110652526A (zh) 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗糖尿病中的应用
CN110652524A (zh) * 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗疼痛中的应用
CN110652516A (zh) * 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
CN110652525A (zh) * 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗炎症中的应用
CN110652523A (zh) * 2018-06-29 2020-01-07 上海绿谷制药有限公司 甘露糖醛二酸的组合物在治疗血管性痴呆症中的应用
CN110652517A (zh) * 2018-06-29 2020-01-07 上海绿谷制药有限公司 褐藻胶寡糖二酸的组合物
CN109156615B (zh) * 2018-09-18 2021-12-28 青岛农业大学 一种利用褐藻寡糖提高动物精液品质的方法
CN109221811A (zh) * 2018-09-28 2019-01-18 福州大学 一种水产饲料添加剂褐藻寡糖的制备方法
CN109260210A (zh) * 2018-10-11 2019-01-25 深圳大学 寡聚甘露糖醛酸在抑制总Tau表达、磷酸化和聚集中的应用
CN109674813A (zh) * 2018-12-12 2019-04-26 大连海洋大学 用于提高雄性动物生理功能的复合制剂
CN110151773A (zh) * 2019-05-13 2019-08-23 深圳大学 寡聚古罗糖醛酸在预防和治疗Tau蛋白病药物中的应用
WO2020227876A1 (fr) * 2019-05-13 2020-11-19 深圳大学 Utilisation d'acide oligo-guluronique dans un médicament pour la prévention et le traitement de maladies liées la protéine tau
CN112336861A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 通过调节氨基酸水平治疗阿尔茨海默病的方法
CN112336876A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 用于识别阿尔茨海默病患者中的糖类药物敏感性患者的方法
CN112336860A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 通过调节肠道微生物治疗阿尔茨海默病的方法
CN112336742A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 甘露糖醛酸寡糖治疗Th1主导相关疾病的用途
CN110615855B (zh) * 2019-11-01 2020-09-15 农业农村部规划设计研究院 一种生物多糖溶降解制备水溶寡聚衍生物的方法
WO2021097288A1 (fr) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions et méthodes de traitement de maladies neurodégénératives
CN110755440B (zh) * 2019-11-20 2023-02-28 中国海洋大学 川芎嗪和甘露糖醛酸的组合物在用于制备治疗血栓性疾病和神经系统疾病的药物中的应用
CN110946804B (zh) * 2020-01-06 2022-07-15 王爱芹 一种预防龋齿和口腔溃疡的漱口水及其制备方法
CN114796243B (zh) * 2021-01-27 2024-04-05 中国海洋大学 一种甘露糖醛酸和益母草碱的药物组合物及其应用
CN115068660A (zh) * 2021-03-11 2022-09-20 吴元通 一种用于创面修复的湿性敷料及其制备方法
CN113730373B (zh) * 2021-07-02 2023-01-24 浙江海洋大学 一种递送姜黄素的zein-AOS复合纳米颗粒及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460945A (en) * 1991-05-30 1995-10-24 Center For Blood Research, Inc. Device and method for analysis of blood components and identifying inhibitors and promoters of the inflammatory response
US5952308A (en) * 1991-07-29 1999-09-14 Pola Chemical Industries Inc. Mineral absorption promoting agent
JPH06237783A (ja) * 1993-02-17 1994-08-30 Maruha Corp アルギン酸カリウムオリゴ糖及びその製造法
US5460957A (en) * 1992-04-28 1995-10-24 Maruha Corporation Calcium alginate oligosaccharide and method for producing the same from potassium or sodium alginate
JP3202365B2 (ja) * 1992-12-04 2001-08-27 株式会社紀文フードケミファ オリゴマンヌロン酸を重合度によって分離する方法
JPH1143439A (ja) * 1997-07-30 1999-02-16 Maruha Corp 血管内皮増殖促進剤
AU2178000A (en) * 1998-12-11 2000-06-26 Salk Institute For Biological Studies, The Co-factors for trophic factors, and methods of use thereof
JP4186294B2 (ja) * 1999-02-26 2008-11-26 セイコーエプソン株式会社 ポリグルロン酸の製造方法
KR100501584B1 (ko) * 2000-02-03 2005-07-18 (주)케이비피 저분자 폴리만유로네이트의 제조방법, 혈청지질개선제로서의 이의 신규 용도 및 이를 함유하는 기능성식품 및 건강 보조 식품
ATE303406T1 (de) * 2000-05-12 2005-09-15 Seiko Epson Corp Verfahren zur herstellung von polyuronsäuren
CN1117766C (zh) * 2000-09-07 2003-08-13 青岛海洋大学 单一聚合度的甘露糖醛酸的制备方法
CN1341664A (zh) * 2000-09-07 2002-03-27 青岛海洋大学 聚甘露糖醛酸多糖的制备方法及应用
JP2002272420A (ja) * 2001-03-19 2002-09-24 Maruha Corp 抗高血圧関連摂取物
CN1161368C (zh) * 2001-04-07 2004-08-11 青岛海洋大学 一种褐藻胶寡糖的制造方法
CN1160080C (zh) 2001-10-01 2004-08-04 青岛海洋大学 褐藻胶寡糖作为制备预防因东莨菪碱所致痴呆药物的应用
CN1401786A (zh) * 2001-11-15 2003-03-12 青岛海洋大学 β－D－甘露糖醛酸寡糖单克隆抗体的制备方法
FR2840305B1 (fr) * 2002-05-29 2005-08-19 Ct D Etude Et De Valorisation Procedes d'obtention d'oligo-mannuronates et guluronates, les produits obtenus et leurs utilisations
CN1182146C (zh) * 2002-09-20 2004-12-29 青岛海洋大学 一种利用化学氧化制备褐藻胶寡糖的方法
CN1454992A (zh) * 2003-05-16 2003-11-12 中国海洋大学 一种新的褐藻胶裂合酶及其制备方法和应用
CN1473836A (zh) * 2003-08-04 2004-02-11 中国海洋大学 还原端1位为羧基的古罗糖醛酸寡糖及其衍生物
CN1486988A (zh) * 2003-08-04 2004-04-07 中国海洋大学 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物
CN1562050A (zh) 2004-03-24 2005-01-12 中国海洋大学 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用

Also Published As

Publication number Publication date
EP1736160A4 (fr) 2013-01-09
US20170112870A1 (en) 2017-04-27
AU2005223923A1 (en) 2005-09-29
EP1736160B1 (fr) 2015-08-26
EA200601756A1 (ru) 2007-04-27
DK1736160T3 (en) 2015-12-07
EA011417B1 (ru) 2009-02-27
AU2005223923B2 (en) 2008-10-23
BRPI0509217A8 (pt) 2018-03-13
KR20070007397A (ko) 2007-01-15
BRPI0509217B1 (pt) 2020-09-24
US8835403B2 (en) 2014-09-16
PL1736160T3 (pl) 2016-01-29
JP2007530718A (ja) 2007-11-01
BRPI0509217B8 (pt) 2022-11-16
NO341226B1 (no) 2017-09-18
JP4709203B2 (ja) 2011-06-22
NO20064825L (no) 2006-12-27
UA85226C2 (ru) 2009-01-12
WO2005089776A1 (fr) 2005-09-29
BRPI0509217A (pt) 2007-09-04
EP1736160A1 (fr) 2006-12-27
CA2561873A1 (fr) 2005-09-29
PT1736160E (pt) 2015-11-20
HUE028071T2 (en) 2016-11-28
ES2552218T3 (es) 2015-11-26
US20070254848A1 (en) 2007-11-01
KR100844918B1 (ko) 2008-07-09
US20190255092A1 (en) 2019-08-22
ZA200608813B (en) 2008-01-08
CN1562050A (zh) 2005-01-12
US10213456B2 (en) 2019-02-26
US20150105344A1 (en) 2015-04-16
CA2561873C (fr) 2013-01-15
US9493496B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
MA28971B1 (fr) Oligosaccharides d'algine et derives de ceux-ci ainsi que leur fabrication et leur utilisation
Elburki et al. A novel chemically modified curcumin reduces severity of experimental periodontal disease in rats: initial observations
MA30514B1 (fr) Nouveaux composes.
MA27316A1 (fr) Derives d'indoline-phenylsulfonamide
MA33274B1 (fr) Dérivés de la thiéno [2, 3-b] pyridine servant d'inhibiteurs de réplication virale
EP1853590A1 (fr) Composés hétérocycliques liquéfiés et leur utilisation comme modulateurs de sirtuine
MA29693B1 (fr) Derives de xanthine en tant qu'agonistes hm74a selectifs
CN102388054A (zh) 噻唑并吡啶沉默调节蛋白调节剂的化合物
EP1853610A1 (fr) Dérivés de n-phénylbenzamide en tant qu'agents régulant la sirtuine
KR20130112880A (ko) 다중불포화 장쇄 케톤을 사용한 류마티스성 관절염 치료법
WO2006094210A2 (fr) Modulateurs de sirtuine de tetrahydroquinoxalinone
US4734421A (en) Anti-inflammatory substituted 2-benzyl-mercapto-imidazole and pyrimidine derivatives compositions and method of use therefor
WO2017191827A1 (fr) Polyrotaxane dégradable intérieurement et son procédé de synthèse
CN1040741A (zh) 抗酸成纤维细胞生长因子复合物及其治疗胃肠道遗疡病的方法
WO2006094233A1 (fr) Modulateurs de sirtuine isothiourée n,n’-dicyclique
CN1036135A (zh) 生长抑制剂及其应用
WO2006094248A1 (fr) Modulateurs de sirtuine cycliques a substitution aryle
HUP9902079A2 (hu) A mátrix metalloproteinázok működését gátló aromás ketosavak és azok származékai
FR2751964A1 (fr) Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
Ferre et al. New insights into the regulation of liver inflammation and oxidative stress
CA1047501A (fr) Derives hydroxyles ou carboxyles du benzimidazole et leur procede de preparation
FR2374288A1 (fr) Nouvelles interphenylenes-11,12-secoprostaglandines utiles comme medicaments
CA2434052A1 (fr) Utilisation d'une rheine pour la preparation d'un medicament pour le traitement d'un taux eleve d'il-1
BE902257A (fr) Procede de praparation du d-glucose et de produits d'hydrolyse de l'amidon.
FR2747123A1 (fr) Nouveaux derives diarylmethylidene tetrahydrofurane, leurs procedes de preparation, et leurs utilisations en therapeutique